BRIEF published on 03/19/2025 at 12:35, 1 year 3 months ago Valerio Therapeutics Board Meeting Decisions Director Changes Shareholder Meeting Share Split Board Resolutions Article Amendments
PRESS RELEASE published on 03/19/2025 at 12:30, 1 year 3 months ago Informations privilégiées / Autres communiqués Rapport du conseil d'administration de VALERIO THERAPEUTICS pour l'AG mixte des actionnaires du 9 avril 2025 concernant révocations, cooptations, division du nominal des actions et modifications statutaires Cooptation Revocation Valerio Therapeutics AG Mixte Division Du Nominal
PRESS RELEASE published on 03/19/2025 at 12:30, 1 year 3 months ago Inside Information / Other news releases Valerio Therapeutics Board of Directors convenes a General Meeting with resolutions on director dismissals, co-optation, share division, bylaws amendment, and formalities powers Board Of Directors General Meeting Resolutions Valerio Therapeutics Share Division
BRIEF published on 02/04/2025 at 10:40, 1 year 4 months ago Valerio Therapeutics opts for strategic refocusing Clinical Trials Oncology Financial Strategy Medical Innovation Valerio Therapeutics
BRIEF published on 02/04/2025 at 10:40, 1 year 4 months ago Valerio Therapeutics opte pour un recentrage stratégique Innovation Médicale Stratégie Financière Essais Cliniques Oncologie Valerio Therapeutics
PRESS RELEASE published on 02/04/2025 at 10:35, 1 year 4 months ago Informations privilégiées / Autres communiqués Valerio Therapeutics annonce un recentrage stratégique pour se concentrer sur le développement de médicaments early-stage et assurer une croissance durable. La société cherche un accord de financement à long terme Développement Financement Restructuration Médicaments Valerio Therapeutics
PRESS RELEASE published on 02/04/2025 at 10:35, 1 year 4 months ago Inside Information / Other news releases Valerio Therapeutics refocuses strategy, discontinuing clinical trials for financial reasons. Focus on early-stage drug development Clinical Trials Financial Challenges Valerio Therapeutics Strategy Refocus Early-stage Development
BRIEF published on 10/01/2024 at 00:56, 1 year 8 months ago Valerio Therapeutics Reports First Half 2024 Financial Results Financial Results R&D Clinical Trial Valerio Therapeutics Single Domain Antibodies
BRIEF published on 10/01/2024 at 00:56, 1 year 8 months ago Valerio Therapeutics publie ses résultats financiers du premier semestre 2024 Résultats Financiers R&D Essai Clinique Valerio Therapeutics Anticorps À Domaine Unique
PRESS RELEASE published on 10/01/2024 at 00:51, 1 year 8 months ago Inside Information: News release on accounts, results Valerio Therapeutics annonce ses résultats financiers du Premier Semestre 2024 et fait le point sur ses activités, y compris l'acquisition d'Emglev Therapeutics et le développement de la plateforme PlatONTM Résultats Financiers Biotechnologie Valerio Therapeutics Emglev Therapeutics Plateforme PlatONTM
Published on 06/27/2026 at 16:50, 22 hours 56 minutes ago Redwood AI Announces Definitive Agreement with Quantum.IQ and Expands into Quantum Resistant Cyber Security
Published on 06/27/2026 at 01:40, 1 day 14 hours ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 1 day 15 hours ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 1 day 16 hours ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 1 day 16 hours ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/27/2026 at 00:05, 1 day 15 hours ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 1 day 15 hours ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 16 hours ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 16 hours ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 1 day 16 hours ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
